Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Implantable Cardiac Defibrillator Use Significantly Lowers Heart Failure Mortality

09.03.2004


The use of an implantable cardiac defibrillator (ICD) can provide a significant reduction in mortality in heart failure patients, according to a study coordinated by researchers from the Duke Clinical Research Institute.



"Treatment using conventional therapy plus an implantable cardiac defibrillator showed a statistically significant reduction in total mortality when compared to standard treatment with a placebo and standard treatment with amiodarone, an anti-arrhythmia drug," said Kerry L. Lee, Ph.D., an associate professor of biostatistics at Duke and principal investigator of the data coordinating center of the trial.

Results of the trial, called SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial), were presented today (March 8, 2004) at the American College of Cardiology scientific sessions. The trial was sponsored by the National Heart, Lung and Blood Institute (NHLBI). Medtronic, Inc., Minneapolis, supplied the ICDs and Wyeth Pharmaceuticals, Madison, N.J., supplied the amiodarone and placebo pills. Lee has no financial interests in either company.


Currently, more than 5 million Americans suffer from congestive heart failure (CHF), with more than 400,000 new cases diagnosed annually. CHF is a condition of decreased or impaired function of the heart muscle resulting in an inability to pump sufficient blood through the body. Patients with CHF also have a higher risk of abnormal heart rhythm, known as arrhythmia, which often leads to sudden cardiac death. About half of all CHF patients who die do so from sudden cardiac death.

"With the population growing older, chronic heart failure will become a much more significant problem in the United States," Lee noted.

Traditionally, CHF is treated with ACE inhibitors, beta blockers, diuretics, statins and aspirin to improve the heart’s efficiency. This study’s goal was to determine whether adding a cardiac defibrillator or anti-arrhythmia medication to standard therapies could reduce the risk of sudden cardiac death. An ICD is a small device implanted beneath the skin which corrects abnormal heart rhythms when they occur by providing a controlled electrical impulse to the heart.

In the study, 2,521 patients were enrolled in 148 centers, including Duke, in the United States, Canada and New Zealand. All participants had been diagnosed with moderate to severe CHF, otherwise known as Class II and Class III, according to the New York Heart Association classification system for heart failure. Seventy-seven percent of participants were men, with minorities making up 23 percent of the total. Study participants ranged in age from 19 to 90, with the median age being 60.

Most participants were receiving multiple drugs to treat their CHF. 85 percent were receiving ACE inhibitors; 70 percent digoxin; 69 percent beta blockers; 56 percent aspirin; 38 percent statins; 34 percent warfarin; and 14 percent angiotensin II receptor blocker (ARB).

Participants were randomly entered into three study arms in equal proportions: conventional therapy plus a placebo; conventional therapy plus amiodarone; and conventional therapy plus ICD. The drug arms of the trial were double-blinded so that neither the patient nor the medical providers knew who were receiving placebo or amiodarone. Patients were enrolled from September 1997 through July 2001 and were followed until October 2003.

"What we found was that patients with the ICD had a three-year mortality rate of 17.1 percent compared to 22.4 percent for those receiving placebo and 24 percent for those receiving amiodarone," Lee said. "After five years, the mortality for the ICD patients was 28.9 percent while the amiodarone patients had a 34 percent mortality rate and the placebo patients 36.1 percent.

"It is a significant achievement any time you can find a reduction in mortality of that amount," Lee continued.

When the study ended, 666 participants had died: 182 (22 percent) in the ICD group, 240 (28 percent) in the amiodarone group and 244 (29 percent) in the placebo group.

Lee noted that Class II CHF patients achieved the most significant reduction in mortality from the ICD therapy as compared to the Class III patients.

"It seemed that the more severe the case of heart failure, the more likely the patient died from causes other than arrhythmias which aren’t helped by an ICD," Lee explained.

Lee also noted that the ICD reduced deaths equally for patients whose CHF resulted from heart attack, or ischemia, (52 percent of patients in the trial)and for those patients whose heart failure was due to non-ischemic causes, such as hypertension or a virus.

Duke served as the data-coordinating center for the trial. The study director was Gust H. Bardy, M.D., of the Seattle Institute for Cardiac Research, which served as the clinical coordinating center. Other study leaders were Daniel B. Mark, M.D., from Duke; and Robin Boineau, M.D., and Michael Domanski, M.D., of the NHLBI.

Richard Puff | dukemed news
Further information:
http://dukemednews.org/news/article.php?id=7453

More articles from Health and Medicine:

nachricht Potential seen for tailoring treatment for acute myeloid leukemia
10.12.2018 | University of Washington Health Sciences/UW Medicine

nachricht UC San Diego researchers develop sensors to detect and measure cancer's ability to spread
06.12.2018 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers develop method to transfer entire 2D circuits to any smooth surface

What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.

Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...

Im Focus: Three components on one chip

Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.

Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...

Im Focus: Substitute for rare earth metal oxides

New Project SNAPSTER: Novel luminescent materials by encapsulating phosphorescent metal clusters with organic liquid crystals

Nowadays energy conversion in lighting and optoelectronic devices requires the use of rare earth oxides.

Im Focus: A bit of a stretch... material that thickens as it's pulled

Scientists have discovered the first synthetic material that becomes thicker - at the molecular level - as it is stretched.

Researchers led by Dr Devesh Mistry from the University of Leeds discovered a new non-porous material that has unique and inherent "auxetic" stretching...

Im Focus: The force of the vacuum

Scientists from the Theory Department of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science (CFEL) in Hamburg have shown through theoretical calculations and computer simulations that the force between electrons and lattice distortions in an atomically thin two-dimensional superconductor can be controlled with virtual photons. This could aid the development of new superconductors for energy-saving devices and many other technical applications.

The vacuum is not empty. It may sound like magic to laypeople but it has occupied physicists since the birth of quantum mechanics.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

Expert Panel on the Future of HPC in Engineering

03.12.2018 | Event News

 
Latest News

Small but ver­sat­ile; key play­ers in the mar­ine ni­tro­gen cycle can util­ize cy­anate and urea

10.12.2018 | Life Sciences

New method gives microscope a boost in resolution

10.12.2018 | Physics and Astronomy

Carnegie Mellon researchers probe hydrogen bonds using new technique

10.12.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>